The Wetherby-based firm said the development with the life sciences division of the South Korean LG Group has triggered an undisclosed milestone payment.
Dr. Alastair Smith, chief executive of Avacta, said: "I am delighted with the progress in our important strategic partnership with LG Chem. LG Chem is a world-class drug development partner with excellent biologics manufacturing and clinical development capabilities and a pioneering vision to develop innovative drugs.
"I am particularly pleased that we have achieved this significant milestone with a novel Affimer bispecific product, which highlights the tremendous promise of the Affimer platform."
Avacta is developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer and pre|CISION platforms.
Avacta and LG Chem have a multi-target therapeutics development agreement to develop Affimer therapeutics in several disease areas.
As part of the agreement, LG Chem has the exclusive rights to develop and commercialise across the world Avacta's Affimer PD-L1 inhibitor with Affimer XT serum half-life extension.
LG Chem has successfully completed certain pre-clinical in-vivo models leading to the selection of a pre-clinical candidate for further development towards the clinic and triggering an undisclosed milestone payment.
The partnership also provides LG Chem with rights to develop and commercialise other Affimer and non-Affimer biotherapeutics combined with Affimer XT half-life extension for a range of indications and Avacta could earn up to $55m in milestone payments for each of these new products.
In addition, under the agreement Avacta will earn royalties on all future Affimer XT product sales by LG Chem.
Support The Yorkshire Post and become a subscriber today.
Your subscription will help us to continue to bring quality news to the people of Yorkshire. In return, you'll see fewer ads on site, get free access to our app and receive exclusive members-only offers.
So, please - if you can - pay for our work. Just £5 per month is the starting point. If you think that which we are trying to achieve is worth more, you can pay us what you think we are worth. By doing so, you will be investing in something that is becoming increasingly rare. Independent journalism that cares less about right and left and more about right and wrong. Journalism you can trust.